Overview
- Disc Medicine’s bitopertin review was extended to February 10 as regulators questioned the trial’s “pain‑free time in the sun” endpoint and evaluated possible abuse risk.
- Sanofi’s bid to expand Tzield for late‑stage type 1 diabetes was pushed back over serious adverse events, with the FDA citing a treatment‑related death and seeking details on seizure and clotting cases.
- Scheduling documents indicate other priority picks have slipped, with Boehringer Ingelheim’s zongertinib now expected in mid‑February and Eli Lilly’s orforglipron targeted for April 10.
- HHS said FDA divisions can adjust timelines at their discretion, and only one product to date—a generic Augmentin XR—has been approved through the voucher initiative.
- Industry sources describe hesitancy to enter the program due to perceived legal exposure and concerns over politicization, even as some experts view the delays as evidence of reviewer caution.